Cargando…
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression
Lack of eradication of disseminated breast cancer by chemotherapy is a central clinical problem. Even tumors that show substantial shrinkage after drug treatment frequently relapse and eventually become refractory to all drugs available. The mechanisms underlying this lack of eradication are largely...
Autores principales: | Rottenberg, Sven, Jonkers, Jos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053122/ https://www.ncbi.nlm.nih.gov/pubmed/23127286 http://dx.doi.org/10.1186/bcr3327 |
Ejemplares similares
-
Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids
por: Paes Dias, Mariana, et al.
Publicado: (2022) -
Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
por: Montes de Jesus, Filipe Miguel, et al.
Publicado: (2023) -
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
por: Gupta, Avinash, et al.
Publicado: (2019) -
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
por: Yamanaka, Kinrin, et al.
Publicado: (2017) -
Par-4 prevents breast cancer recurrence
por: Hebbar, Nikhil, et al.
Publicado: (2013)